ライフサイエンスコーパス: observation group

1 maintenance group and 603 in the placebo or observation group).

2 e (three from the SRS group and one from the observation group).

3 usions (transfusion group) or standard care (observation group).

4 ) or nodal observation with ultrasonography (observation group).

5 Thirty-two patients served as controls (observation group).

6 ease (61 in the vitespen group and 63 in the observation group).

7 rum GH response 28.2 mU/L [6.8]) acted as an observation group.

8 dissection group and in 6.3% of those in the observation group.

9 ars (with the same dose schedule), or to the observation group.

10 year trastuzumab group, and 15 (0.9%) in the observation group.

11 ation alone, and 87 patients enrolled in the observation group.

12 ab group, and 36 (5%) of 672 patients in the observation group.

13 because of melanoma versus 139 (95%) in the observation group.

14 group, and 146 (22%) of 672 patients in the observation group.

15 vacizumab group and 25 months (17-37) in the observation group.

16 halidomide-prednisone and 34.1 months in the observation group.

17 with thalidomide-prednisone versus 6 in the observation group.

18 atients in the vitespen group and 367 in the observation group.

19 had longer 5- and 10-year survival than the observation group.

20 Neither response predicted survival in the observation group.

21 1% to 21%) were observed in the adjuvant and observation groups.

22 s not significantly greater than that of the observation group (+0.16 SDS [0.20]).

23 In the observation group, 14 of 97 children (14%) had an end-po

24 red forty-four patients were assigned to the observation group, 143 patients to receive 20 mg/m2 of f

25 reatment group (77 percent) and 9 men in the observation group (18 percent) were alive and had no evi

26 gnificantly different in the PDL treated and observation groups (25, 42%, vs 27, 44%; p=0.92).

27 in 10 of the 165 participants (6.1%) in the observation group (3 of these 10 started treatment witho

28 group, 49 patients) or no further treatment (observation group, 46 patients) for the brain metastasis

29 ie of neurologic causes than patients in the observation group (6 [14%] of 43 who died vs 17 [44%] of

30 y higher in the dissection group than in the observation group (68+/-1.7% and 63+/-1.7%, respectively

31 87.2% (95% CI, 83.1% to 90.5%) in the direct-observation group, 74.0% (CI, 68.9% to 78.6%) in the sel

32 Eighty-eight patients (61%) in the observation group, 83 (58%) in the fluorouracil plus fol

33 was similar in the dissection group and the observation group (86+/-1.3% and 86+/-1.2%, respectively

34 equent in the radiotherapy group than in the observation group (9 [18%] of 49 vs 32 [70%] of 46; P<.0

35 The observation group also suffered 3 serious hernia-related

36 ed in the biopsy group, as compared with the observation group, among patients with intermediate-thic

37 cal recurrence was 43% (95% CI 31-59) in the observation group and 72% (60-87) in the SRS group (haza

38 in 4.6% (4 of 87) of the participants in the observation group and in 2.2% (2 of 90) of the participa

39 erioration occurred in 2.3% (2 of 87) of the observation group and in 2.2% (2 of 90) of the patching

40 s were as follows: 15 of 152 patients in the observation group and two of 160 patients in the enoxapa

41 vival did not differ between maintenance and observation groups and pooled data were used.

42 operative treatment of appendix mass (active observation group) and incidence of severe complications

43 e ofatumumab group vs 23 [10%] of 237 in the observation group) and infections (31 [13%] vs 20 [8%]).

44 (two in the vitespen group and seven in the observation group), and 124 patients with baseline metas

45 In the observation group, at 10 years' follow-up, 19 patients w

46 rall survival (P = .07) as compared with the observation group, but had severe treatment-related toxi

47 ree survival rate was 86.7% +/- 9.5% for the observation group, compared with 69.2% +/- 13% and 40.7%

48 0 years, regardless of treatment assignment (observation group: DFS HR age </= 40 v > 40 years, 1.18;

49 e chemotherapy group and four (0.25%) in the observation group died from non-colorectal cancer causes

50 group and three (1%) of 237 patients in the observation group had adverse events that led to permane

51 the chemotherapy group and 50 (3.1%) in the observation group had missing follow-up.

52 in the vitespen group and 31 (27.0%) in the observation group (hazard ratio 0.576, 95% CI 0.324-1.02

53 in the vitespen group and 146 (39.8%) in the observation group (hazard ratio 0.923, 95% CI 0.729-1.16

54 s-free estimate, 13.2 years) of those in the observation group (hazard ratio [HR], 0.75; 95% CI, 0.55

55 rred with PEG-IFN-alpha-2b versus 406 in the observation group (hazard ratio [HR], 0.87; 95% CI, 0.76

56 as higher in the rituximab group than in the observation group (hazard ratio for death, 0.50; 95% CI,

57 % in the biopsy group and 73.1+/-2.1% in the observation group (hazard ratio for recurrence[corrected

58 ide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0

59 red with 6.7 (95% CI, 6.0-7.5) months in the observation group (hazard ratio, 0.55 [95% CI, 0.44-0.69

60 hereas it was 86.0 months for the placebo or observation group (hazard ratio, 0.75; 95% CI, 0.63 to 0

61 bevacizumab group compared with those in the observation group (HR 0.83, 95% CI 0.70-0.98, p=0.03), b

62 maximally tolerable doses compared with the observation group in the European Organization for Resea

63 The observation group (median follow-up, 55 months) had a me

64 ly longer in the treatment group than in the observation group (median not reached vs. 21 months; haz

65 either the bevacizumab group (n=671) or the observation group (n=672).

66 , 132 patients were randomly assigned to the observation group (n=68) or SRS group (n=64), with 128 p

67 nces (73 in the vitespen group and 76 in the observation group), nine deaths before recurrence (two i

68 hs related to adverse events occurred in the observation group; no deaths were attributed to the stud

69 erapy, with median time to treatment for the observation group of 12 months (range, 4 to 128 months).

70 Randomization to the observation group, older age, thinner central corneal th

71 ion, with lymphadenectomy for nodal relapse (observation group), or wide excision and sentinel-node b

72 nd between intravitreal bevacizumab group vs observation group (P = .45) Steroid-induced cataract was

73 78% for the interferon group and 77% for the observation group (P =.65).

74 s was 1.4 in the biopsy group and 3.3 in the observation group (P<0.001), indicating disease progress

75 b group versus 64% (95% CI, 55 to 73) in the observation group (P<0.001).

76 mediate-treatment group and in 16 men in the observation group (P<0.01).

77 therapy, as compared with 58% and 71% in the observation group (P=.0006 for DFS and P=.02 for OS).

78 b group versus 61% (95% CI, 51 to 70) in the observation group (P=0.001).

79 d died, as compared with 18 of 51 men in the observation group (P=0.02).

80 b group versus 80% (95% CI, 72 to 88) in the observation group (P=0.04).

81 0 deaths in the vitespen group and 72 in the observation group (p=0.896); however, overall survival d

82 and IgM titers were similar for vaccine and observation groups (P =.184).

83 more quality-of-life-adjusted time than the observation group regardless of the relative valuations

84 ASCT were 52% and 53% for the rituximab and observation groups, respectively (P = .7).

85 difference, 6% to 34%) between adjuvant and observation groups, respectively, were observed.

86 ilities were 82% and 49% in the adjuvant and observation groups, respectively.

87 0% (P =.041 unadjusted) for the adjuvant and observation groups, respectively.

88 884 (52%) patients assigned to the observation group selectively crossed over to receive tr

89 higher in the trastuzumab group than in the observation group (severe CHF, 0.8% v 0.0%; confirmed si

90 were better for the SLNB group than for the observation group, specifically among patients with inte

91 In the observation group, the disease recurred in 42 men; 13 of

92 In the observation group, the median survival was 35.2 months (

93 ths in the chemotherapy group and 370 in the observation group; the relative risk of death from any c

94 ces in the chemotherapy group and 359 in the observation group; the relative risk of recurrence with

95 disease-free survival (DFS) from 40% for the observation group to 70% for the treatment group.

96 ients), and the rate of nodal relapse in the observation group was 15.6% (78 of 500 patients).

97 ariate analysis, the survival profile of the observation group was statistically superior to that of

98 the primary end point in the transfusion and observation groups was 2.0 and 4.8 events, respectively,

99 patients in the vitespen group and 42 in the observation group were excluded from the ITT population

100 Cases in the observation group were more likely to demonstrate nevus

101 to withdrawal of consent; two in the active observation group were withdrawn because they became ine

102 or plano spectacles for the children in the observation group who did not need spectacles.

103 nt group and 127 events and 91 deaths in the observation group, with 5-year disease-free survival rat